S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:MOR

MorphoSys Stock Forecast, Price & News

$24.20
+0.10 (+0.41 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.73
Now: $24.20
$24.50
50-Day Range
$24.10
MA: $28.05
$30.66
52-Week Range
$18.21
Now: $24.20
$35.73
Volume165,301 shs
Average Volume49,100 shs
Market Capitalization$3.18 billion
P/E Ratio115.24
Dividend YieldN/A
Beta1.03
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
MorphoSys logo

Headlines

MorphoSys Appoints Sung Lee As CFO
January 6, 2021 |  nasdaq.com
MorphoSys Appoints Sung Lee as Chief Financial Officer
January 6, 2021 |  finance.yahoo.com
MorphoSys AG: Corporate Calendar 2021
December 17, 2020 |  finance.yahoo.com
MorphoSys AG (MOR) Investor Presentation - Slideshow
December 8, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MOR
CUSIPN/A
CIKN/A
Phone49 89 89927 0
Employees640
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$80.43 million
Book Value$3.49 per share

Profitability

Net Income$-115,380,000.00

Miscellaneous

Market Cap$3.18 billion
Next Earnings Date3/17/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.40 out of 5 stars

Medical Sector

1721st out of 1,972 stocks

Pharmaceutical Preparations Industry

705th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$24.20
+0.10 (+0.41 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MorphoSys (NASDAQ:MOR) Frequently Asked Questions

Is MorphoSys a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MorphoSys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View analyst ratings for MorphoSys
or view top-rated stocks.

What stocks does MarketBeat like better than MorphoSys?

Wall Street analysts have given MorphoSys a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MorphoSys wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release its next quarterly earnings announcement on Wednesday, March 17th 2021.
View our earnings forecast for MorphoSys
.

How has MorphoSys' stock price been impacted by COVID-19?

MorphoSys' stock was trading at $25.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MOR stock has decreased by 4.2% and is now trading at $24.20.
View which stocks have been most impacted by COVID-19
.

What guidance has MorphoSys issued on next quarter's earnings?

MorphoSys updated its FY 2020 After-Hours earnings guidance on Monday, March, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $390.717-390.717 million, compared to the consensus revenue estimate of $390.25 million.

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:
  • Dr. Jean-Paul Kress, Chairman of Management Board, MD & CEO (Age 56)
  • Dr. Malte Peters M.D., Chief R&D Officer and Member of the Management Board (Age 59)
  • Mr. Sung H. Lee, CFO & Member of Management Board (Age 51)
  • Dr. Roland Wandeler Ph.D., COO & Member of Management Board (Age 49)
  • Mr. Klaus De Wall, Head of Accounting & Tax
  • Ms. Lara Smith Weber, Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban, Head of Discovery Alliances & Technologies
  • Dr. Anja Pomrehn, Sr. VP & Head of Investor Relations
  • Dr. Armin Weidmann, Head of Compliance and Quality Assurance
  • Ms. Charlotte Lohmann, Sr. VP & Gen. Counsel (Age 51)

What is Simon E. Moroney's approval rating as MorphoSys' CEO?

5 employees have rated MorphoSys CEO Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among MorphoSys' employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of MorphoSys' key competitors?

When did MorphoSys IPO?

(MOR) raised $200 million in an IPO on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

What is MorphoSys' stock symbol?

MorphoSys trades on the NASDAQ under the ticker symbol "MOR."

Who are MorphoSys' major shareholders?

MorphoSys' stock is owned by a number of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.21%), Morgan Stanley (0.16%), Vident Investment Advisory LLC (0.04%), Jane Street Group LLC (0.02%), Sei Investments Co. (0.02%) and Clearbridge Investments LLC (0.02%).

Which major investors are selling MorphoSys stock?

MOR stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Candriam Luxembourg S.C.A., Sei Investments Co., RMB Capital Management LLC, and Clearbridge Investments LLC.

Which major investors are buying MorphoSys stock?

MOR stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Vident Investment Advisory LLC, OneAscent Financial Services LLC, OneAscent Wealth Management LLC, Capital Asset Advisory Services LLC, Comerica Bank, and JPMorgan Chase & Co..

How do I buy shares of MorphoSys?

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately $24.20.

How much money does MorphoSys make?

MorphoSys has a market capitalization of $3.18 billion and generates $80.43 million in revenue each year. The company earns $-115,380,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

How many employees does MorphoSys have?

MorphoSys employs 640 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.com.

Where are MorphoSys' headquarters?

MorphoSys is headquartered at SEMMELWEISSTR. 7, PLANEGG 2M, 82152.

How can I contact MorphoSys?

MorphoSys' mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The company can be reached via phone at 49 89 89927 0 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.